Clinical Efficacy of Sacubitril Valsartan Combined with Recombinant Hu-man Brain Natriuretic Peptide in the Treatment of Heart Failure
Objective The aim of this study was to investigate the clinical efficacy of recombinant human B-type brain natriuretic peptide(rhBNP)in combination with sacubitril valsartan(SV)in the treatment of acute heart failure and its effect on inflammatory factors and oxidative stress indicators.Methods 202 patients with acute heart failure who were hospi-talised in the Department of cardiology of department of cardiovascular,Zhangjiagang Aoyang hospital,from March 2020 to March 2023 were selected and divided into the observation group(n=101)and the control group(n=101)according to the random number table method.The control group received standard treatment for heart failure,and the observation group used rhBNP and SV in combination on this basis.Cardiac function,inflammatory factors and oxidative stress levels were assessed before and after treatment,and statistically analysed.Results The effective rate of treatment in the observation group was 91.09%,which was significantly higher than that of 79.21%in the control group(P=0.023).After treatment,the cardiac index and left ventricular ejection fraction of the observation group were significantly improved,and the heart rate was signifi-cantly reduced(P＜0.01).The inflammatory factors IL-6 and TNF-α were significantly reduced,the oxidative stress indica-tor MDA was significantly decreased,and GSH-Px was significantly increased in the observation group after treatment(P＜0.05).Conclusion The combination of rhBNP and SV in the treatment of patients with acute heart failure can significantly improve the efficacy,improve cardiac function and myocardial injury,as well as effectively regulate the level of inflammatory response and oxidative stress,which has a good prospect for clinical application.
Sacubitril valsartanRecombinant human brain natriuretic peptideHeart failureCombined treatment
国家科技期刊平台
NSTL
万方数据
